Inhibition of Murine AIDS by Combination of AZT and DDCTP-Loaded Erythrocytes
The human acquired immunodeficiency syndrome (AIDS) is a complex disease induced by the human immunodeficiency virus (1, 2). The development of effective therapies for AIDS has been limited by the lack of animal models that exactly mimic events in human disease. Murine AIDS (MAIDS) is a disease that shares many similarities with human AIDS such as splenomegaly, hypergammaglobulinemia, lymphoadenopathy, T- and B-lymphocyte dysfunctions and profound immunodeficiency (3–5). Since many features of this syndrome are common to those defined in human AIDS, MAIDS serve as a useful experimental model for understanding the pathogenesis of AIDS as well as searching for anti-HIV drugs. In our laboratory this animal model has been used to evaluate the efficacy and toxicity of drugs belonging to the nucleoside analogue family (6, 7), known to be potent in vitro and in vivo inhibitors of HIV-1 replication. Unfortunately, the efficacy of drugs so far used in monotherapy is of limited duration while a number of preliminary studies have already shown that combination therapy is more effective than monotherapy (8, 9). Combination therapy may provide additive or synergistic effect of combined drugs, decreased toxicity and delay of viral resistance. Furthermore, treatment can include drugs acting at different levels of HIV replication or protecting different cell types (i.e. lymphocytes and macrophages). Monocyte/macrophages are important target cells for the human immunodeficiency virus type 1 (HIV-1) (10, 11). They may be chronic recervoirs of HIV-1 and probably play an important role in the pathogenesis of AIDS-related complications such as dementia.
KeywordsHuman Immunodeficiency Virus Nucleoside Analogue Acquire Immunodeficiency Syndrome G6PD Gene Symptomatic Human Immunodeficiency Virus
Unable to display preview. Download preview PDF.
- 1.Barrè-Sinoussi, F., J.C. Chermann, F. Rey, M.T. Nugeyre, S. Chamaret, J. Gruest, C. Dauget, C. Axler-Blin, F. Vezinet, C. Ronzioux, W. Rozembaum and L. Montagnier (1983). Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immunodeficiency syndrome (AIDS). Science, 220, 868–871.PubMedCrossRefGoogle Scholar
- 3.Mosier, D.E., R.A. Yetter and H.C. III Morse (1985). Retrovirus induction of acute lymphoproliferative disease and profound immunosuppression in adult C57BL/6 mice. J. Exp. Med. 61, 767–772.Google Scholar
- 6.Brandi, G., A. Casablanca, G.F. Schiavano, L. Rossi, A. Fraternale, A. Albano and M. Magnani (1995). Efficacy and toxicity of long-term administration of 2′,3′-dideoxycytidine in the LP-BM5 murine-induced immunodeficiency model. Antiv. Chem. & Chemother. 6(3), 153–161.Google Scholar
- 7.Rossi, L., G. Brandi, A. Fraternale, G.F. Schiavano, L. Chiarantini and M. Magnani (1993). Inhibition of murine retrovirus induced immunodeficiency disease by dideoxycytidine and dideoxycytidine 5′-triphosphate. J. of AIDS 6, 1179–1186.Google Scholar
- 8.Yarchoan, R.K.M., J.A. Lietzau, B.-Y. Nygen, O.W. Brawley, J.M. Pluda, K.M. Wyvill, S.M. Steinberg, R. Agbaria, H. Mitsuya and S. Broder (1994). A randomized pilot study of alternating and simultaneous regimens of zidovudine (AZT) and didanosine (ddI) in patients with symptomatic human immunodeficiency virus (HIV) infection. J. Infect. Dis. 169, 9–17.PubMedCrossRefGoogle Scholar
- 9.Johnson, V.A., P. Merrill, T.C. Chou and M.S. Hirsch (1992). Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor R. 31-8959 and zidovudine, 2′,3′-dideoxycytidine, or recombinant interferon alfa against zidovudine-sensitive or resistant HIV-1 in vitro. J. Infect. Dis. 166, 1143–1146.PubMedCrossRefGoogle Scholar
- 12.Magnani, M., A. Casabianca, L. Rossi, A. Fraternale, G. Brandi, L. Silvotti and G. Piedimonte (1995). Inhibition of HIV-1 and LP-BM5 replication in macrophages by dideoxycytidine and dideoxycytidine 5′-triphosphate. Antiv. Chem. & Chemother., 6(5), 312–319.Google Scholar
- 14.Ohnota, H., Y Okada, H. Ushijima, T. Kitamura, K. Komuro and T. Mizuochi (1990). 3′-azido-3′-deoxythymidine prevents induction of murine acquired immunodeficiency syndrome in C57BL/10 mice infected with LP-BM5 murine leukemia viruses, a possible animal model for antiretroviral drug screening. Antimicr. Agents and Chemother., 34(4), 605–609.CrossRefGoogle Scholar